Back to News
Market Impact: 0.15
Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care
Source: Nasdaq
Healthcare & Biotech
Profound Medical and Telix Pharmaceuticals announced a co-education agreement to inform physicians and prostate cancer centers about the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided T—; the article text is cut off before the procedure or any further terms are specified. No financial terms or market reaction are reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
PRN0.40
TLX0.40
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here
- Alignment Healthcare Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Alignment Healthcare (ALHC)
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)